Breast cancer tumors in deep tissue imaging with bi-modal NIR/MRI probe
| Project/Area Number |
21K15577
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Tokyo University of Science |
|---|
Principal Investigator |
ドアン テイキンユン 東京理科大学, 研究推進機構生命医科学研究所, 助教 (70838870)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Project Status |
Granted (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2023: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2022: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2021: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | OTN-NIR / MRI / Herceptin / multimodal imaging / breast cancer / herceptin / Her 2 / Breast cancer / Bioimaging / Imaging probe |
|---|
| Outline of Research at the Start |
This project develops a bimodal OTN-NIR and MR imaging probe for targeting breast cancer. MRI can navigate and localize cancer tumors in the body. OTN-NIR can provide volumetric images of tumors with high sensitivity and resolution. This probe is promising for using in surgical aid imaging.
|
| Outline of Annual Research Achievements |
In this fiscal year, the developed bimodal magnetic resonance imaging (MRI)/ and near-infrared fluorescence probe conjugating to Herceptin (~ 40 nm) for HER2 breast cancer targeting. The probe composed of PLGA-b-PEG micelles encapsulating IR-1061 in the core and gadolinium-tetraazacyclododecanetetraacetic acid (Gd-DOTA) conjugated at the border of PLGA/PEG. Herceptin was then conjugated through their amine residues via EDC/NHS chemistry. The study aims to assess the performance of the designed bimodal imaging probe for detecting of breast cancers and determine the optimal conditions in vitro in order to assess the detection limit of the probe, we evaluated the specific binding activities of probe concentrations.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
We could developed the imaging probe for HER2 (+) breast cancer targeting. The important question is if the presence of Herceptin have any negative effect on the imaging properties. Therefore, we promoted for the screening the best conditions for detecting of breast cancers and determine the optimal conditions in vitro, in which the authors focus on the influence of carboxyl groups and their effects on probe behaviors. In order to assess the detection limit of the probe, we evaluated the specific binding activities of probe concentrations. We found the best conditions for the probe detecting antigen.
The optimal condition allowed the probe maintaining its OTN-NIR/MRI properties while performing the detection of the HER-2 antigen.
|
| Strategy for Future Research Activity |
The results are going to be reported at several international conferences. Besides, based on the results obtained from the experiment, papers were prepared and will be submitted.
|
Report
(2 results)
Research Products
(12 results)
